Reviewing Pain Therapeutics (PTIE) & Its Peers
Pain Therapeutics (NASDAQ: PTIE) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Pain Therapeutics to related businesses based on the strength of its valuation, dividends, risk, analyst recommendations, institutional ownership, earnings and profitability.
Volatility & Risk
Pain Therapeutics has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Pain Therapeutics’ rivals have a beta of 5.96, indicating that their average share price is 496% more volatile than the S&P 500.
This table compares Pain Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pain Therapeutics||N/A||-$14.85 million||-2.18|
|Pain Therapeutics Competitors||$284.28 million||$34.29 million||135.41|
Pain Therapeutics’ rivals have higher revenue and earnings than Pain Therapeutics. Pain Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
36.2% of Pain Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 32.7% of Pain Therapeutics shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent ratings and target prices for Pain Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pain Therapeutics Competitors||848||3199||11595||230||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.25%. Given Pain Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Pain Therapeutics has less favorable growth aspects than its rivals.
This table compares Pain Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pain Therapeutics Competitors||-5,347.19%||-434.30%||-39.94%|
Pain Therapeutics rivals beat Pain Therapeutics on 9 of the 12 factors compared.
Pain Therapeutics Company Profile
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company’s drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.